Budapest, Hungary – Liege, Belgium – 23 December 2020 – 7:30 CET –Gedeon Richter Plc. (‘Richter’) and Estetra S.A, the wholly owned subsidiary of Mithra (Euronext Brussels: MITRA), today announced that they have extended their partnership and signed a license and supply agreement for the commercialization of Estelle®, a novel 15 mg estetrol (E4) / 3 mg drospirenone containing combined oral contraceptive, in order to include key markets in Latin America. The product candidate is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues combined with additional benefits of drospirenone.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024